Last reviewed · How we verify
Fufangshuanghua granule
Fufangshuanghua granule is a Small molecule drug developed by China Academy of Chinese Medical Sciences. It is currently FDA-approved.
Fufangshuanghua granule, developed by the China Academy of Chinese Medical Sciences, is a marketed traditional Chinese medicine with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Fufangshuanghua granule |
|---|---|
| Sponsor | China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fufangshuanghua granule CI brief — competitive landscape report
- Fufangshuanghua granule updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI